Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (>= 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy

NCT01045681 is registered in ClinicalTrials.gov with Intergroupe Francophone du Myelome as lead sponsor.

NCT NCT01045681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01045681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (>= 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy
Lead sponsor
Intergroupe Francophone du Myelome
Phase
Phase 2
Overall status
Completed
Start date
March 3, 2010
Completion date
March 28, 2013
Enrollment
75 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma